UPB (Upstream Bio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by UPB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | MICHAEL GRAY | CFO and COO | Sell | — | — |
| 2026-06-17 | Aaron Deykin | Chief Medical Officer | Sell | — | — |
| 2026-06-17 | Everett Rand Sutherland | Chief Executive Officer | Sell | — | — |
| 2026-06-17 | Adam Houghton | Chief Business Officer | Sell | — | — |
| 2026-06-17 | Allison Ambrose | General Counsel | Sell | — | — |
| 2026-06-11 | Marcella K. Ruddy | Director | A | — | — |
| 2026-06-11 | Harold Edward Fleming | Director | A | — | — |
| 2026-06-11 | Ronald C Renaud JR | Director | A | — | — |
| 2026-06-11 | Daniella Beckman | Director | A | — | — |
| 2026-06-11 | Erez Chimovits | Director | A | — | — |
| 2026-06-11 | Liam Ratcliffe | Director | A | — | — |
| 2026-03-17 | Adam Houghton | Chief Business Officer | Sell | — | — |
| 2026-03-17 | Everett Rand Sutherland | Chief Executive Officer | Sell | — | — |
| 2026-03-17 | Aaron Deykin | Chief Medical Officer | Sell | — | — |
| 2026-03-17 | Allison Ambrose | General Counsel | Sell | — | — |
| 2026-03-17 | MICHAEL GRAY | CFO and COO | Sell | — | — |
| 2026-01-06 | Everett Rand Sutherland | Chief Executive Officer | A | — | — |
| 2026-01-06 | Aaron Deykin | Chief Medical Officer | A | — | — |
| 2026-01-06 | Adam Houghton | Chief Business Officer | A | — | — |
| 2026-01-06 | Allison Ambrose | General Counsel | A | — | — |
| 2026-01-06 | MICHAEL GRAY | CFO and COO | A | — | — |
| 2025-06-12 | Erez Chimovits | Director | A | — | — |
| 2025-06-12 | Harold Edward Fleming | Director | A | — | — |
| 2025-06-12 | Marcella K. Ruddy | Director | A | — | — |
| 2025-06-12 | Liam Ratcliffe | Director | A | — | — |
| 2025-06-12 | Ronald C Renaud JR | Director | A | — | — |
| 2025-06-12 | Daniella Beckman | Director | A | — | — |
| 2025-02-07 | Allison Ambrose | General Counsel | A | — | — |
| 2025-02-07 | MICHAEL GRAY | CFO and COO | A | — | — |
| 2025-02-07 | Aaron Deykin | Chief Medical Officer | A | — | — |
| 2025-02-07 | Adam Houghton | Chief Business Officer | A | — | — |
| 2025-02-07 | Everett Rand Sutherland | Chief Executive Officer | A | — | — |
| 2024-12-17 | Allison Ambrose | General Counsel | A | — | — |
| 2024-10-17 | Erez Chimovits | Director | MIXED | — | — |
| 2024-10-17 | AI Upstream LLC | 10%+ Owner | MIXED | — | — |
| 2024-10-17 | OrbiMed Advisors Israel II Ltd | Director | MIXED | — | — |
| 2024-10-15 | Daniella Beckman | Director | A | — | — |
| 2024-10-15 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | C | — | — |
| 2024-10-15 | Ronald C Renaud JR | Director | A | — | — |
| 2024-10-15 | Erez Chimovits | Director | A | — | — |
| 2024-10-15 | Harold Edward Fleming | Director | A | — | — |
| 2024-10-15 | Marcella K. Ruddy | Director | A | — | — |
| 2024-10-15 | Liam Ratcliffe | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,494,410 | — |
| — | Director | 4,554,873 | — |
| — | Director | 973,716 | — |
| — | 10%+ Owner | 894,733 | — |
| — | Chief Executive Officer | 70,812 | — |
| — | Chief Medical Officer | 33,197 | — |
| — | CFO and COO | 28,795 | — |
| — | Chief Business Officer | 23,601 | — |
| — | General Counsel | 16,048 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the UPB quote page; the site-wide leaderboard is on the insider transactions hub.